Corient Capital Partners’s GSK GSK Stock Holding History

Corient Capital Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$347K	Buy	7,970 +1,594	+25%	+$60.4K	0.03%	422
2022 Q2	$347K	Sell	6,376 -666	-9%	-$36.8K	0.03%	433
2022 Q1	$383K	Buy	7,042 +428	+6%	+$23.2K	0.03%	451
2021 Q4	$365K	Buy	6,614 +1,984	+43%	+$103K	0.02%	455
2021 Q3	$221K	Buy	+4,630	New	+$233K	0.02%	605
2020 Q1	–	Sell	-4,708	Closed	-$277K	–	441
2019 Q4	$277K	Buy	4,708 +426	+10%	+$23.7K	0.04%	374
2019 Q3	$228K	Buy	+4,282	New	+$220K	0.03%	383

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Corient Capital Partners's GSK Position: Q3 2022 in Review

Corient Capital Partners increased its GSK (GSK) stake by 25% in Q3 2022, buying an estimated $60.4K and bringing the position to 7,970 shares worth $347K. The position accounts for 0.03% of the portfolio, ranked #422.

Corient Capital Partners first reported a position in GSK in Q3 2019 and has held it in 7 quarters since. The position peaked at $383K in Q1 2022. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Corient Capital Partners held 7,970 shares of GSK worth $347K as of Q3 2022.
Corient Capital Partners bought 1,594 GSK shares in Q3 2022, an estimated $60.4K.
GSK made up 0.03% of Corient Capital Partners's portfolio in Q3 2022, its #422 holding.
Corient Capital Partners first reported a position in GSK in Q3 2019 and has held it in 7 quarters since.
Corient Capital Partners's GSK position peaked at $383K in Q1 2022.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.